Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 34: 1387-1391, 1988;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fagnart, O. C.
Right arrow Articles by Laterre, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fagnart, O. C.
Right arrow Articles by Laterre, C.

Clinical Chemistry, Vol 34, 1387-1391, Copyright © 1988 by American Association for Clinical Chemistry

Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system

OC Fagnart, CJ Sindic and C Laterre
Laboratory of Neurochemistry, Catholic University of Louvain, Brussels, Belgium.

S100 protein (S100) was assayed by particle counting immunoassay in serum samples from 50 healthy individuals, 325 patients with various neurological disorders, and 20 patients with malignant melanoma. The detection limit for this protein was 0.3 microgram/L. We detected none in healthy individuals or in 50 patients with multiple sclerosis, 23 with dementia, or 20 with meningitis. S100 was detectable in serum of only a few patients with meningoradiculitis (2/20), peripheral neuropathy (2/30), encephalitis (1/14), Guillain-Barre syndrome (1/25), or AIDS (2/20). In contrast, we observed high concentrations in 29 of 75 patients with tumors of the central nervous system, especially in meningioma (6/9), glioblastoma (9/23), and neurinoma (5/5). Values for S100 were mainly abnormally high (greater than 0.3 microgram/L) in serum from patients with cerebrovascular disorders (43/48) or with metastases of melanoma (9/11).


The following articles in journals at HighWire Press have cited this article:


Home page
 Mol. Cell. ProteomicsHome page
C. G. Zimmermann-Ivol, P. R. Burkhard, J. Le Floch-Rohr, L. Allard, D. F. Hochstrasser, and J.-C. Sanchez
Fatty Acid Binding Protein as a Serum Marker for the Early Diagnosis of Stroke: A Pilot Study
Mol. Cell. Proteomics, January 1, 2004; 3(1): 66 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
G. S. O. A. Missotten, N. E. M. L. Tang, C. M. Korse, H. M. H. Hurks, D. de Wolff-Rouendaal, J. E. E. Keunen, M. J. Jager, and J. M. G. Bonfrer
Prognostic Value of S-100-{beta} Serum Concentration in Patients With Uveal Melanoma
Arch Ophthalmol, August 1, 2003; 121(8): 1117 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
F. Michetti and D. Gazzolo
S100B Protein in Biological Fluids: A Tool for Perinatal Medicine
Clin. Chem., December 1, 2002; 48(12): 2097 - 2104.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
W. Jordan, J. Hagedohm, J. Wiltfang, G. Laier-Groeneveld, H. Tumani, A. Rodenbeck, E. Ruther, and G. Hajak
Biochemical markers of cerebrovascular injury in sleep apnoea syndrome
Eur. Respir. J., July 1, 2002; 20(1): 158 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
D. N. Derkach, H. Okamoto, and S. Takahashi
Neuronal and Astroglial Injuries in Patients Undergoing Coronary Artery Bypass Grafting and Aortic Arch Replacement During Hypothermic Cardiopulmonary Bypass
Anesth. Analg., November 1, 2000; 91(5): 1066 - 1072.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. Ettinger, A. B. Laumark, R. M. Ostroff, J. Brundell, W. A. Baumgartner, and A. Y. Razumovsky
A new optical immunoassay for detection of S-100B protein in whole blood
Ann. Thorac. Surg., December 1, 1999; 68(6): 2196 - 2201.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Takahashi, A. Chamczuk, Y. Hong, and G. Jackowski
Rapid and Sensitive Immunoassay for the Measurement of Serum S100B Using Isoform-specific Monoclonal Antibody
Clin. Chem., August 1, 1999; 45(8): 1307 - 1311.
[Full Text] [PDF]

Home page
 JCOHome page
M. Deichmann, A. Benner, M. Bock, A. Jackel, K. Uhl, V. Waldmann, and H. Naher
S100-Beta, Melanoma-Inhibiting Activity, and Lactate Dehydrogenase Discriminate Progressive From Nonprogressive American Joint Committee on Cancer Stage IV Melanoma
J. Clin. Oncol., June 1, 1999; 17(6): 1891 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A. Raabe, D. K Menon, S. Gupta, M. Czosnyka, and J. D Pickard
Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study
J. Neurol. Neurosurg. Psychiatry, December 1, 1998; 65(6): 930 - 932.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
O. Nygaard, B. Langbakk, and B. Romner
Age- and Sex-Related Changes of S-100 Protein Concentrations in Cerebrospinal Fluid and Serum in Patients with No Previous History of Neurological Disorder
Clin. Chem., March 1, 1997; 43(3): 541 - 543.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Association for Clinical Chemistry.